Transscleral vs transpupillary diode laser photocoagulation for the treatment of zone II type 1 retinopathy of prematurity: Anatomical and refractive outcomes

Background/Aim. The aim of the study was to investigate the outcomes of temporal Zone II-sparing laser photocoagulation combined with intravitreal bevacizumab (IVB) in patients with Type 1 retinopathy of prematurity (ROP) in Zone I.Methods. Medical records of 74 eyes of 37 infants were analysed. Only infants with Type 1 ROP in Zone I were included. Thirty-two eyes were treated with temporal-sparing laser + IVB. Both Zone I and temporal Zone II were spared to minimise potential visual field loss. Forty-two eyes were treated with laser alone conventionally. Early treatment outcomes, late complications, and refractive errors were analysed.Results. The mean gestational age and birth weight of the enrolled patients were 25.7 ± 2.5 weeks and 798.8 ± 440.2 g, respectively. In the combined treatment group, plus sign regression was achieved faster (12.1 ± 6.2 days vs. 25.6 ± 21.3 days,p=0.011) and retreatment was required less (0% vs. 23.8%,p=0.004) than in the laser-alone group. Retinal/preretinal haemorrhages occurred more often in the laser-alone group (42.9% vs. 9.4%,p=0.002). Normal development of temporal retinal vessels was also observed in twelve eyes in the combined treatment group. No differences in late complications or refractive errors were observed between the groups.Conclusion. Temporal Zone II-sparing laser treatment combined with IVB showed good early treatment outcome and temporal retinal vessels development.

Download Full-text

Strukturelle, visuelle und refraktive Verläufe der intravitrealen Injektion von Aflibercept bei Hochrisiko-Frühgeborenen-Prethreshold-Retinopathie vom Typ 1

Karger Kompass Ophthalmologie ◽

10.1159/000438802 ◽

2015 ◽

Vol 1 (2) ◽

pp. 84-86

Keyword(s):

High Risk ◽

Retinopathy Of Prematurity ◽

Intravitreale Injektion ◽

Multizentrische Studie ◽

Refractive Outcomes ◽

Intravitreal Aflibercept ◽

Zone Ii

Zielsetzung: Untersuchung der strukturellen, visuellen und refraktiven Ergebnisse der intravitrealen Injektion von Aflibercept in Monotherapie bei Patienten mit Frühgeborenenretinopathie (retinopathy of prematurity; ROP) vom Typ 1 mit hohem Risiko und unterhalb der Therapieschwelle. Aufbau: Prospektive, nichtrandomisierte, interventionelle Fallserien-Studie. Patienten und Methoden: Patienten mit Hochrisiko-Prethreshold-Typ-1-ROP wurden mit 1 mg/0,025 ml Aflibercept intravitreal behandelt. Die betrachteten primären Endpunkte waren ein ungünstiger struktureller Verlauf, ungünstiger visueller Verlauf und ungünstiger refraktiver Verlauf. Die sekundären Endpunkte waren ausbleibende Rezidivierung, okulare und systemische Nebenwirkungen. Ergebnisse: In die Studie wurden 26 Augen aufgenommen; alle hatten eine Nachbeobachtung von 1 Jahr abgeschlossen. Das mittlere Geburtsgewicht betrug 991 ± 266 g (Bereich 875-1105 g); das mittlere Gestationsalter bei Entbindung betrug 26,33 ± 2,1 Wochen (Bereich 24-30 Wochen); bei 9 Augen wurde die ROP als Stadium 2+, Zone I eingestuft, bei 14 Augen lag Stadium 3+ in Zone II vor und bei 3 Augen Stadium 3 in Zone I. 25 Augen (96,2%) zeigten einen günstigen strukturellen und 21 (80,1%) einen günstigen visuellen Verlauf; die Fehlsichtigkeit lag nach 1 Jahr im Median bei 0,75 dpt (Bereich -9,5 bis +4). Schlussfolgerungen: Die intravitreale Injektion von Aflibercept als Monotherapie ist eine einfache, sichere und wirksame Therapieoption bei Hochrisiko-Prethreshold-ROP vom Typ 1. Eine weitere, multizentrische Studie mit längerem Nachbeobachtungszeitraum ist erforderlich. Übersetzung aus Salman AG, Said AM: Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity. Ophthalmic Res 2015;53:15-20 (DOI: 10.1159/000364809)

Download Full-text

Refractive outcomes of laser-treated and non-laser-treated retinopathy of prematurity at Hospital Selayang: a 2-year retrospective review

Malaysian Journal of Ophthalmology ◽

10.35119/myjo.v3i4.228 ◽

2021 ◽

Vol 3 (4) ◽

pp. 210-222

Author(s):

Aasiah Ahmad Sharifuddin ◽

Fiona Lee Min Chew ◽

Irina Effendi-Tenang ◽

Amir Samsudin

Keyword(s):

Retinopathy Of Prematurity ◽

Retrospective Review ◽

High Myopia ◽

Laser Photocoagulation ◽

Treated Group ◽

Refractive Outcomes ◽

Zone Ii ◽

The Mean ◽

The Difference

Objective: To compare the refractive outcomes of laser-treated and non-laser-treated retinopathy of prematurity (ROP) infant, at 2 years of age in Hospital Selayang.Methods: Retrospective review involving patients born between 2016 and 2018. They were divided into those who were treated with laser photocoagulation, and those who were observed. Laser treatment was given to infants with threshold and high-risk, pre-threshold disease. Refractive error was identified by cycloplegic refraction at 2 years of age.Results: There were 22 eyes from 11 infants in the laser-treated group, all of which had zone II ROP with plus disease; of these, four had stage 2 ROP and 18 had stage 3 ROP. There were 53 eyes from 28 patients in the non-laser-treated group. The mean birth weight for the laser-treated and non-laser-treated groups was 966.9 ± 92.6 g and 1019.3 ± 282.0 g, respectively (P = 0.398). Mean gestational age for the laser-treated and non-laser-treated groups was 28.2 ± 2.2 weeks and 27.7 ± 2.2 weeks, respectively (P = 0.390). At 2 years, the mean spherical equivalence for the laser-treated and non-laser treated groups was -0.55 ± 2.49 D and +0.17 ± 1.43 D, respectively, although the difference was not statistically significant (P = 0.120). Myopia was commoner in the laser-treated group (six eyes [27%] vs five eyes [9%], P = 0.047), and two eyes from two different infants (10%) from this group also developed high myopia (> -6.00 D). For hypermetropia and astigmatism, there were no statistically significant differences between the groups (all P > 0.05). High myopia was strongly related to the post-conceptual age when receiving laser therapy (P = 0.025). In the laser-treated group, two infants (9%) had amblyopia and one (5%) had exotropia at 2 years of age. None of the eyes developed structural retinal sequelae.Conclusion: Despite successful treatment of ROP, a significant number of laser-treated eyes developed myopia. This highlights the need for long-term refractive screening in these patients.

Download Full-text

Comparison of intravitreal bevacizumab injection and laser photocoagulation for type 1 zone II retinopathy of prematurity

Journal of Current Ophthalmology ◽

10.1016/j.joco.2018.10.008 ◽

2019 ◽

Vol 31 (1) ◽

pp. 61-65 ◽

Cited By ~ 4

Author(s):

Ramak Roohipoor ◽

Hamidreza Torabi ◽

Reza Karkhaneh ◽

Mohammad Riazi-Eafahani

Keyword(s):

Retinopathy Of Prematurity ◽

Laser Photocoagulation ◽

Intravitreal Bevacizumab ◽

Intravitreal Bevacizumab Injection ◽

Zone Ii ◽

Bevacizumab Injection

Download Full-text

Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity

British Journal of Ophthalmology ◽

10.1136/bjophthalmol-2017-311662 ◽

2018 ◽

Vol 103 (4) ◽

pp. 494-498 ◽

Cited By ~ 4

Author(s):

Yichen Bai ◽

Huanjie Nie ◽

Shiyu Wei ◽

Xiaohe Lu ◽

Xiaoyun Ke ◽

...

Keyword(s):

Retinopathy Of Prematurity ◽

Laser Photocoagulation ◽

Primary Outcome ◽

Safety And Efficacy ◽

Postmenstrual Age ◽

Zone Ii ◽

The Mean ◽

Secondary Outcomes ◽

Number Of Injections

BackgroundTo evaluate the safety and efficacy of intravitreal conbercept (IVC) injection in the treatment of retinopathy of prematurity (ROP).MethodsPatients with ROP who underwent IVC injection in Zhujiang Hospital from June 2015 to July 2016 were studied retrospectively. The primary outcome was defined as the regression of plus disease. The secondary outcomes were defined as the presence of recurrence, number of injections and the final regression of disease.ResultsA total of 48 eyes of 24 patients with ROP were included. Among them, 9 eyes of 5 patients had zone I ROP, 35 eyes of 18 patients had zone II ROP and 4 eyes of 2 patients had aggressive posterior ROP. The mean gestational age was 28.5±1.6 weeks, the mean birth weight was 1209.6±228.6 g, the mean postmenstrual age of first injection was 34.2±1.9 weeks and the mean follow-up period was 31.0±4.7 weeks. Forty of 48 eyes (83.3%) received IVC only once, and the regression of plus disease occurred at an average of 3.5±1.5 weeks after the first injection of conbercept. For eight recurrent eyes (16.7%), four eyes received a second IVC and the remaining four eyes received laser photocoagulation, and the regression of plus disease occurred in 3 weeks. No lens opacity, vitreous haemorrhage, entophthalmia or retinal detachment was observed during follow-up.ConclusionIVC injection is an effective treatment for ROP.

Download Full-text